Terms: = Gastric cancer AND CYLD, CYLD1, 1540, ENSG00000083799, USPL2, KIAA0849, CYLDI, CDMT, HSPC057, FLJ31664, FLJ20180, EAC
206 results:
1. Phenotypic immune characterization of gastric and esophageal adenocarcinomas reveals profound immune suppression in esophageal tumor locations.
Groen-van Schooten TS; Harrasser M; Seidel J; Bos EN; Fleitas T; van Mourik M; Pouw RE; Goedegebuure RSA; Doeve BH; Sanders J; Bos J; van Berge Henegouwen MI; Thijssen VLJL; van Grieken NCT; van Laarhoven HWM; de Gruijl TD; Derks S
Front Immunol; 2024; 15():1372272. PubMed ID: 38638445
[TBL] [Abstract] [Full Text] [Related]
2. Treatment of esophageal adenocarcinoma in patients with a history of bariatric surgery.
Nobel T; Sewell M; Boerner T; Bains MS; Bott MJ; Gerdes H; Gray K; Nishimura M; Park BJ; Shah P; Sihag S; Jones DR; Molena D
J Gastrointest Surg; 2024 Apr; 28(4):337-342. PubMed ID: 38583881
[TBL] [Abstract] [Full Text] [Related]
3. [Clinicopathological factors and clinical significance of No.12b lymph node metastasis in gastric antrum cancer].
Zhang B; Zheng GL; Zhang Y; Zhao Y; Zhu HT; Zhang T; Liu Y; Zheng ZC
Zhonghua Wei Chang Wai Ke Za Zhi; 2024 Feb; 27(2):167-174. PubMed ID: 38413085
[No Abstract] [Full Text] [Related]
4. Evaluation of factors influencing long-term and textbook outcomes in laparoscopic gastrectomy.
Lin X; Tan C; Wu W; Liang C; Qian F; Zhao Y
Eur J Surg Oncol; 2024 Mar; 50(3):108002. PubMed ID: 38330541
[TBL] [Abstract] [Full Text] [Related]
5. [Barrett's esophagus: Diagnosis, treatment and minimizing of risk].
Thorell A; Bednarska O; Jeremiasen M; Mottacki N; Lundell L
Lakartidningen; 2023 Sep; 120():. PubMed ID: 37746770
[TBL] [Abstract] [Full Text] [Related]
6. Reflux conditions induce E-cadherin cleavage and EMT via APE1 redox function in oesophageal adenocarcinoma.
Lu H; Cao LL; Ballout F; Belkhiri A; Peng D; Chen L; Chen Z; Soutto M; Wang TC; Que J; Giordano S; Washington MK; Chen S; McDonald OG; Zaika A; El-Rifai W
Gut; 2023 Dec; 73(1):47-62. PubMed ID: 37734913
[TBL] [Abstract] [Full Text] [Related]
7. Cost-effectiveness analysis of nivolumab plus chemotherapy vs chemotherapy for patients with unresectable advanced or metastatic HER2-negative gastric or gastroesophageal junction or esophageal adenocarcinoma in Japan.
Morimoto K; Moriwaki K; Shimozuma K; Nakayama T
J Gastroenterol; 2023 Dec; 58(12):1188-1197. PubMed ID: 37725256
[TBL] [Abstract] [Full Text] [Related]
8. Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced gastric/Gastroesophageal Junction cancer or Esophageal Adenocarcinoma From CheckMate 649.
Moehler M; Xiao H; Blum SI; Elimova E; Cella D; Shitara K; Ajani JA; Janjigian YY; Garrido M; Shen L; Yamaguchi K; Liu T; Schenker M; Kowalyszyn R; Bragagnoli AC; Bruges R; Montesarchio V; Pazo-Cid R; Hunter S; Davenport E; Wang J; Kondo K; Li M; Wyrwicz L
J Clin Oncol; 2023 Dec; 41(35):5388-5399. PubMed ID: 37713657
[TBL] [Abstract] [Full Text] [Related]
9. Predicting Incident Adenocarcinoma of the Esophagus or gastric Cardia Using Machine Learning of Electronic Health Records.
Rubenstein JH; Fontaine S; MacDonald PW; Burns JA; Evans RR; Arasim ME; Chang JW; Firsht EM; Hawley ST; Saini SD; Wallner LP; Zhu J; Waljee AK
Gastroenterology; 2023 Dec; 165(6):1420-1429.e10. PubMed ID: 37597631
[TBL] [Abstract] [Full Text] [Related]
10. The tight junction protein claudin 6 is a potential target for patient-individualized treatment in esophageal and gastric adenocarcinoma and is associated with poor prognosis.
Simon AG; Lyu SI; Laible M; Wöll S; Türeci Ö; Şahin U; Alakus H; Fahrig L; Zander T; Buettner R; Bruns CJ; Schroeder W; Gebauer F; Quaas A
J Transl Med; 2023 Aug; 21(1):552. PubMed ID: 37592303
[TBL] [Abstract] [Full Text] [Related]
11. American Society for Gastrointestinal Endoscopy guideline on endoscopic submucosal dissection for the management of early esophageal and gastric cancers: summary and recommendations.
; Forbes N; Elhanafi SE; Al-Haddad MA; Thosani NC; Draganov PV; Othman MO; Ceppa EP; Kaul V; Feely MM; Sahin I; Buxbaum JL; Calderwood AH; Chalhoub JM; Coelho-Prabhu N; Desai M; Fujii-Lau LL; Kohli DR; Kwon RS; Machicado JD; Marya NB; Pawa S; Ruan W; Sheth SG; Storm AC; Thiruvengadam NR; Qumseya BJ;
Gastrointest Endosc; 2023 Sep; 98(3):271-284. PubMed ID: 37498266
[TBL] [Abstract] [Full Text] [Related]
12. American Society for Gastrointestinal Endoscopy guideline on endoscopic submucosal dissection for the management of early esophageal and gastric cancers: methodology and review of evidence.
Al-Haddad MA; Elhanafi SE; Forbes N; Thosani NC; Draganov PV; Othman MO; Ceppa EP; Kaul V; Feely MM; Sahin I; Ruan Y; Sadeghirad B; Morgan RL; Buxbaum JL; Calderwood AH; Chalhoub JM; Coelho-Prabhu N; Desai M; Fujii-Lau LL; Kohli DR; Kwon RS; Machicado JD; Marya NB; Pawa S; Ruan W; Sheth SG; Storm AC; Thiruvengadam NR; Qumseya BJ;
Gastrointest Endosc; 2023 Sep; 98(3):285-305.e38. PubMed ID: 37498265
[TBL] [Abstract] [Full Text] [Related]
13. Tumor monocyte content predicts immunochemotherapy outcomes in esophageal adenocarcinoma.
Carroll TM; Chadwick JA; Owen RP; White MJ; Kaplinsky J; Peneva I; Frangou A; Xie PF; Chang J; Roth A; Amess B; James SA; Rei M; Fuchs HS; McCann KJ; Omiyale AO; Jacobs BA; Lord SR; Norris-Bulpitt S; Dobbie ST; Griffiths L; Ramirez KA; Ricciardi T; Macri MJ; Ryan A; Venhaus RR; Van den Eynde BJ; Karydis I; Schuster-Böckler B; Middleton MR; Lu X;
Cancer Cell; 2023 Jul; 41(7):1222-1241.e7. PubMed ID: 37433281
[TBL] [Abstract] [Full Text] [Related]
14. Signaling Pathways in the Pathogenesis of Barrett's Esophagus and Esophageal Adenocarcinoma.
Maslenkina K; Mikhaleva L; Naumenko M; Vandysheva R; Gushchin M; Atiakshin D; Buchwalow I; Tiemann M
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298253
[TBL] [Abstract] [Full Text] [Related]
15. Long-Term Postsurgical Outcomes of Neoadjuvant Chemoradiation (CROSS) Versus Chemotherapy (FLOT) for Multimodal Treatment of Adenocarcinoma of the Esophagus and the Esophagogastric Junction.
Gebauer F; Plum PS; Damanakis A; Chon SH; Popp F; Zander T; Quaas A; Fuchs H; Schmidt T; Schröder W; Bruns CJ
Ann Surg Oncol; 2023 Nov; 30(12):7422-7433. PubMed ID: 37210683
[TBL] [Abstract] [Full Text] [Related]
16. Sex differences in treatment allocation and survival of potentially curable gastroesophageal cancer: A population-based study.
Kalff MC; Dijksterhuis WPM; Wagner AD; Oertelt-Prigione S; Verhoeven RHA; Lemmens VEPP; van Laarhoven HWM; Gisbertz SS; van Berge Henegouwen MI
Eur J Cancer; 2023 Jul; 187():114-123. PubMed ID: 37146505
[TBL] [Abstract] [Full Text] [Related]
17. MicroRNA dysregulation and therapeutic opportunities in esophageal diseases.
Markey GE; Donohoe CL; McNamee EN; Masterson JC
Am J Physiol Gastrointest Liver Physiol; 2023 Jul; 325(1):G1-G13. PubMed ID: 37129237
[TBL] [Abstract] [Full Text] [Related]
18. Linear- Versus Circular-Stapled Esophagojejunostomy During Total Gastrectomy: Systematic Review and Meta-Analysis.
Sozzi A; Aiolfi A; Matsushima K; Bonitta G; Lombardo F; Viti M; Russo A; Campanelli G; Bona D
J Laparoendosc Adv Surg Tech A; 2023 Jun; 33(6):524-533. PubMed ID: 37057962
[No Abstract] [Full Text] [Related]
19. Relationship between Helicobacter Pylori Infection and the Risk of Esophageal cancer in Thailand.
Poosari A; Nutravong T; Namwat W; Sa-Ngiamwibool P; Ungareewittaya P; Boonyanugomol W
Asian Pac J Cancer Prev; 2023 Mar; 24(3):1073-1080. PubMed ID: 36974563
[TBL] [Abstract] [Full Text] [Related]
20. Patients with esophageal adenocarcinoma showed better prognosis than those with adenocarcinoma of the gastroesophageal junction.
Huang Q; Cheng Y; Lew E; Shi J; Wiener D; Weber HC
J Dig Dis; 2023 Feb; 24(2):98-112. PubMed ID: 36970757
[TBL] [Abstract] [Full Text] [Related]
[Next]
